Form 4: ALX Oncology Director Granted 16,833 Stock Options

ALX Oncology Holdings Inc. Director Daniel J. Curran was granted 16,833 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

Summary

• Daniel J. Curran, a Director of ALX Oncology Holdings Inc. (ALXO), was granted 16,833 stock options.
• The options have an exercise price of $1.32 per share.
• The grant date for these options was January 20, 2026.
• The options will vest in 12 equal monthly installments, commencing on February 20, 2026.
• The expiration date for these stock options is January 19, 2036.
• The options represent the right to buy 16,833 shares of ALX Oncology's Common Stock.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents routine director compensation that aligns interests, without indicating any immediate negative operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Stock options are a common form of equity compensation, reflecting standard corporate governance practices.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is typical for equity compensation plans.

Risks

• The value of the stock options is subject to the future market price of ALX Oncology's common stock, which can fluctuate based on company performance, industry trends, and overall market conditions.
• If the stock price does not exceed the exercise price of $1.32, the options may not hold significant value.

Future Outlook

The stock options are subject to a vesting schedule over 12 equal monthly installments beginning February 20, 2026, indicating a future alignment of the director's interests with the company's long-term performance.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries, often used to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• Equity compensation, particularly through stock options, is a prevalent method across the biotech sector for executive and director remuneration, aligning with practices seen in companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• The vesting schedule over 12 months is a common short-to-medium term incentive structure, though longer vesting periods (e.g., 3-4 years) are also typical for broader employee grants.

Related Party Transactions

• The grant of stock options to Daniel J. Curran, a Director of ALX Oncology Holdings Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, but future exercise could lead to minor dilution.
• Director (Daniel J. Curran): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will begin vesting in 12 equal monthly installments starting February 20, 2026.

Key Dates

Keywords

ALX Oncology, ALXO, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting Schedule